Molbio Diagnostics IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Day-wise Subscription (times subscribed)
Financial Analysis
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 840.66 | 1,027.94 | 1,455.17 |
| Expense | 657.83 | 820.41 | 1,221.35 |
| Profit (PAT) | 83.54 | 138.58 | 164.14 |
| Total Assets | 1,221.06 | 1,461.56 | 2,148.42 |
| Company | EPS | P/E | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Poly Medicure Limited | 31.79 | 52.61 | 10.37 | 306.45 | 1,875.26 Cr |
| Dr. Lal Pathlabs Limited | 30.24 | 62.20 | 20.78 | 145.00 | 2,762.91 Cr |
| Metropolis HealthcareLimited | 9.19 | 63.72 | 12.56 | 72.98 | 1,645.85 Cr |
| Vijaya Diagnostics CentreLimited | 16.81 | 81.02 | 18.07 | 93.02 | 814.20 Cr |
Promoters: Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Sriram Natarajan
Strengths & Risks
- Heavily oversubscribed — 70.2x overall (so far).
- Strong institutional (QIB) demand — 186.4x.
- Revenue grew 42% in the latest reported year.
- Solid profit margin — 11.3%.
- Strong return on equity — 16%.
- Largely an offer for sale — most proceeds go to selling shareholders, not the company.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care. Through its wholly owned subsidiary, Bigtec Labs, Molbio has strong research and development capabilities focused on creating diagnostic platforms for point-of-care (POC) testing. From product development to large-scale deployment, the company aims to improve access to reliable and affordable healthcare for everyone.
Molbio Diagnostics Ltd., Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722
| Purpose | Amount (Cr) |
|---|---|
| Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space. | 118.08 |
| Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and | 79.04 |
| General corporate purposes | - |
Resources & Documents
Molbio Diagnostics has set a price band of Rs 768–Rs 807 per share for an issue size of Rs 940 crore. The stock listed with a 21.44% gain versus its issue price on August 17, 2026.
Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour.
The issue is promoted by Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Sriram Natarajan with Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., Motilal Oswal Investment Advisors Ltd. acting as lead manager. Net proceeds will primarily be used towards Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center o… (Rs 118 crore) and Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Uni… (Rs 79 crore).
Grey market is quoting a premium of +Rs 127 (+15.7% over issue price), up Rs 47 from the previous session. Final subscription data records overall subscription at 70.24x, retail at 12.92x, QIB at 186.39x, NII at 49.79x.
On fundamentals, the company is posting revenue growth of 41.6%, a profit margin of 11.3%, return on equity of 15.6% in its most recent reported period. Listed peers in this segment include Poly Medicure Limited (P/E 52.61x) and Dr. Lal Pathlabs Limited (P/E 62.20x) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Strong Subscribe — the data suggests strong listing-day potential backed by healthy fundamentals. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Molbio Diagnostics IPO GMP — What It Means
The latest grey market premium for Molbio Diagnostics IPO is ₹127 (+15.7%). GMP is an unofficial, dealer-quoted figure that hints at expected listing-day demand — it is not a guaranteed listing price. For Molbio Diagnostics it should be read alongside the subscription numbers and the company's fundamentals, since grey-market premiums can swing sharply during the bidding window.
See the full Molbio Diagnostics GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!